Categories
pipeline

SAP-001

SAP-001 is viewed as a novel clinical stage agent with disease modification potential for gout patientswith highly safe, efficacious, well-tolerated and easily administered. SAP-001could be used in patients unable to control their gout with allopurinol.SAP-001 cansignificant reduce uric acid /eliminate the risk of acute gout attack/reduce and/or eliminate tophi.

Over time, focus on gaining acceptance for SAP-001 to be 1st line treatment for Gout, as well as for Gout patients that are not well controlled on allopurinol and/or febuxostat in addition to refractory/tophaceous Gout patients.

Sizeable market potential with $1B+ potential for Gout in US alone.

Categories
pipeline

SAP-002

Chronic pruritus occurs in 13% of the general population without age limitation and affects almost one fifth of the general population leading to great impairment of quality of life. There is a high unmet need here as effective treatment options are still missing.

Unmet needs, such as the standardization of experimental and clinical research protocols, diagnostic procedures and therapeutic regimens, as well as a better understanding of associated burdens and the development of novel effective therapies should be targeted by physicians and researchers dealing with chronic pruritus.